Angiogenesis is essential to the process of neovascularization under both physiological and pathological conditions, including cancer, diabetic retinopathy, rheumatoid arthritis, and ischemia. Angiogenic markers are potential prognostic markers for disease activity and indicators of response to chemotherapy. Various strategies have been designed to target vascular endothelial growth factor receptor (Flt-1/VEGFR) signal transduction. Several VEGF-neutralizing antibodies have been successful in combination with chemotherapy in limiting angiogenesis and tumor progression. Other strategies to target the VEGF/Flt-1 pathway include soluble VEGFRs (Traps), receptor tyrosine-kinase inhibitors that target VEGFR2/Flk-1, and neutralizing aptamers.

MSD provides solutions to support and simplify your angiogenesis & vascular research needs. We offer singleplex and multiplex assays to measure biomarkers such as FGF (basic), FLT-1, Tie-2, and VEGF.